From the outset of the COVID-19 outbreak, MPP realised that equitable access to medicines and treatments would be essential in the fight against this global threat. MPP issued a statement on the 5 February 2020 saying that we stand ready to help in any way.
On the 31 March 2020, MPP’s Board decided to temporarily expand MPP’s mandate to include any health technology that could contribute to the global response to COVID-19 and where licensing could facilitate innovation and access.
MPP understands that broad and affordable access to future health technologies that could be important for the prevention and treatment of COVID-19 will be critical everywhere in the world, and that it is essential to think about the best approaches to make that possible collectively.
MPP is already gathering patent knowledge for products being used in clinical trials and making it available on its patents and licences database, MedsPaL. Already included in the database: remdesivir, lopinavir/ritonavir, favipiravir, ruxolitinib; and the following biologics: tocilizumab, sarilumab and siltuximab.
To ensure you receive our latest information on new products being tested for COVID-19 being added to MedsPaL, follow us on Twitter, LinkedIn and subscribe to the MedsPaL newsletter.
This page will be updated as new information becomes available.
 UN working to fight COVID-19 and achieve Global Goals, United Nations